Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Recently, FDA released two draft guidance documents outlining the transition plan for devices granted an Emergency Use Authorization under the Covid-19 Pandemic to fully legally cleared products. Many of the recommendations in these guidances leave industry professionals without a clear understanding of what FDA is trying to accomplish with the process.
This live webcast will review FDA's proposed recommendations for devices with EUAs, recommended feedback manufacturers and regulatory professionals should provide to FDA prior to guidance finalization, and next steps to anticipate for products with an active EUA.
24 January 2022 - 4 March 2022: Member $0.00 | Nonmember $0.00
By attending this program, you will:
Beginning to intermediate
Content is introductory in nature and requires no requisite knowledge or experience to grasp concepts and related exercises. Basic educational activities are meant to establish a foundation of knowledge and/or competence that will be expanded upon in practice or in higher level activities.
Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.
Any company that currently holds an Emergency Use Authorization and intends to transition the products to legally marketed devices.
Michelle Lott, Principal & Founder
Michelle Lott is founder and principal of leanRAQA. She has supported more than 100 companies with regulatory strategy, regulatory submissions, quality systems compliance, due diligence and technical support services. Lott’s clients delegate these things to her so they can focus on winning in the marketplace. She served a four-year term on the US Food and Drug Administration (FDA) Device Good Manufacturing Practices Advisory Committee (DGMP), and she has completed the RAPS Executive Development Program at the Kellogg School of Management at Northwestern University.
RAPS reserves the right to cancel this program at its sole discretion. RAPS will not be responsible for travel or other costs incurred due to cancellation.
To transfer a registration, email email@example.com with the event title, name of the original registrant and the contact information for the new attendee.
For additional hands-on support, you can also connect with RAPS support 30 min prior to the workshop: https://www.raps.org/website/virtual-event-helpFor account support, contact the RAPS Support Center: +1 301 770 2920, ext. 200 (8:30 am–5:30 pm EST, Monday–Friday) or email firstname.lastname@example.org.